Why do users switch to blast & cruise?

Several cumulative reasons (Coward 2013, Rasmussen 2016): (1) PCTs progressively less effective after each cycle, endogenous T no longer recovers to satisfactory levels; (2) gains drop during off with demotivation; (3) continuous competitive lifestyle (contest prep every 6-12 months) not allowing time for complete off phases; (4) desire to maintain a competitive physique permanently. B&C becomes a compromise for these users, but with increased cardiovascular and fertility risk.

Not necessarily, but difficult to reverse after several years. Smit 2021 (HAARLEM) documents that HPG recovery after moderate cycles is still possible at 12-18 months, but after prolonged B&C (3+ continuous years at repeated supraphysiological doses), ASIH becomes almost permanent in majority of users. Return to endogenous production > 400 ng/dL becomes improbable. The practice therefore becomes engaged long-term, even lifelong. Decision to be made with informed consent.

What monitoring under B&C?

Stricter than under classic cycles. Quarterly panel: CBC (target hematocrit 40 years), E2, T total and free. Annual echocardiography to monitor left ventricular hypertrophy (Baggish 2017). Preventive cardiology evaluation recommended in users > 35 years or with family history. Regular blood donation (target Hct < 50%) if chronic erythrocytosis.

Do classic cycles really preserve long-term health?

Better than B&C, but not as much as claimed. Pope 2014 (Endocrine Society) and Smit 2022 (HAARLEM review) document that even 'clean' repeated cycles generate cardiovascular accumulation (durably degraded HDL, intermittent hypertension, recurrent hematocrit) that can ultimately lead to effects equivalent to unsupervised B&C. The difference: classic cycles leave the possibility of stopping completely (HPG recovery preserved short-term), while B&C commits de facto. For optimal long-term health, minimize cumulated cycles.

How many cycles before probable ASIH?

Variable per individual and protocol. Coward 2013 documents that about 20-30% of chronic users (>5 cumulated cycles) develop persistent hypogonadism requiring permanent TRT. Aggravating factors: long cycles (>16 weeks), strong-suppression compounds (nandrolone, trenbolone), neglected PCTs, age > 35 years, comorbidities. To minimize: limit to 2 cycles per year maximum, moderate durations (12-14 weeks), clean PCTs, off-windows > blast duration, regular biological monitoring.

Incompatible without support. B&C continually suppresses the HPG axis so stops spermatogenesis in a few months. To preserve fertility (Anawalt 2019, Liu 2002, Depenbusch 2002): hCG 500-1000 IU 2× per week SC continuously, in parallel with testosterone. This maintains spermatogenesis in majority of users. Smit 2021 shows that even under optimized protocol, sperm quality remains inferior to baseline. For users wishing to procreate in the near future, B&C not recommended without formal fertility plan.

Getting out of B&C: is it possible?

Difficult but not impossible in young users after short B&C. Smit 2021 (HAARLEM) shows partial HPG recovery at 12-18 months post-stop in some former users, but often incomplete. Possible exit scheme: (1) progressive dose decrease blast → cruise → complete stop over 6-12 months, (2) intensive PCT (hCG 1500 IU EOD × 14 d then clomid 50/25/25/25 + nolvadex 40/20/20/20 × 8 weeks), (3) biological monitoring over 12-24 months, (4) endocrinology consultation for evaluation. For users having done B&C > 5 years at high doses, complete natural recovery becomes improbable and permanent TRT becomes the pragmatic landing function.

Blast & Cruise vs Classic Cycles: complete comparison (continuity vs intermittence)

Q: Do classic cycles really preserve long-term health?

Better than B&C, but not as much as claimed. Pope 2014 (Endocrine Society) and Smit 2022 (HAARLEM review) document that even 'clean' repeated cycles generate cardiovascular accumulation (durably degraded HDL, intermittent hypertension, recurrent hematocrit) that can ultimately lead to effects equivalent to unsupervised B&C. The difference: classic cycles leave the possibility of stopping completely (HPG recovery preserved short-term), while B&C commits de facto. For optimal long-term health, minimize cumulated cycles.

Q: How many cycles before probable ASIH?

Variable per individual and protocol. Coward 2013 documents that about 20-30% of chronic users (>5 cumulated cycles) develop persistent hypogonadism requiring permanent TRT. Aggravating factors: long cycles (>16 weeks), strong-suppression compounds (nandrolone, trenbolone), neglected PCTs, age > 35 years, comorbidities. To minimize: limit to 2 cycles per year maximum, moderate durations (12-14 weeks), clean PCTs, off-windows > blast duration, regular biological monitoring.

Critère	blast-and-cruise	traditional-cycles
Continuity	Continuous (never stops)	Intermittent (blast + off)
HPG axis recovery	None	Between cycles (with PCT)
ASIH risk	Very high	Moderate (with clean PCT)
Cumulative cardio exposure	Continuous, cumulative	Limited to blasts
Fertility	Suppressed (without hCG)	Recoverable post-PCT
Medical follow-up	Essential	Recommended
Target users	Advanced bodybuilders	Seasonal competitors
HPG management	PCT useless (axis suppressed)	Mandatory PCT

Quand choisir blast-and-cruise

Blast and cruise (B&C) is a permanent testosterone practice alternating blast phases (supraphysiological 300-600 mg/week ± additional compounds over 10-16 weeks) and cruise phases (testosterone alone at TRT dose 100-150 mg/week over 8-16 weeks), without ever completely stopping. Choose it (with critical hindsight) for: (1) an advanced bodybuilding practice accepting permanent commitment to exogenous testosterone, (2) a user having already done several cycles with difficult PCTs or limited HPG recovery, (3) a life of continuous competition (repeated contest preparations), (4) a hormonal lifestyle choice assumed after complete evaluation. Pharmacological profile: alternating dose-effects, potential cardiovascular accumulation, permanent HPG suppression. Drawbacks to anticipate (Pope 2014, Endocrine Society, Baggish 2017): cumulative cardiovascular exposure (chronically degraded HDL, hypertension, accelerated left ventricular hypertrophy per Baggish 2017 in chronic users), durable HPG axis suppression (Rasmussen 2016: persistent low endogenous T in former chronic users even long after stopping), fertility suppressed without hCG bridge, essential lifelong medical follow-up (CBC, lipids, PSA, echocardiography). For user accepting these commitments, typical scheme: 16 weeks blast at 500 mg/week testo + compounds, then 12 weeks cruise at 125 mg/week testo alone. Coward 2013 and Smit 2022: ASIH almost inevitable long-term.

Quand choisir traditional-cycles

Classic cycles are the traditional bodybuilding practice: blast 10-16 weeks + PCT 4-6 weeks + off of several months (ideally 1.5× the blast duration). Choose them for: (1) seasonal competitive practice (one or two blasts per year), (2) preservation of natural HPG recovery option, (3) preserved fertility (with hCG as PCT bridge if necessary), (4) flexibility to be able to stop totally at any time, (5) cardiovascular exposure limited to blast windows with recovery between. Pharmacological profile: pulsation of supraphysiological exposure vs natural recovery. Advantages (Smit 2021: HAARLEM cohort): recovery of testicular volume and spermatogenesis documented at 12 months post-cycle in majority of users having done moderate cycles (duration < 16 weeks, moderate dose, clean PCT). Drawbacks: post-cycle fatigue during HPG recovery, partial loss of visible gains (water retention, glycogen), need for correct PCT to minimize ASIH (Coward 2013). Typical scheme: testo 400-500 mg/week × 12 weeks + PCT (hCG + clomid + nolvadex 4-6 weeks) + off 6 months minimum before next cycle. For young users (< 35 years) with documented HPG recovery.

Combinaison ?

Blast & cruise and classic cycles are philosophically opposed protocols: one chooses one OR the other. However, some users alternate over time: first do several years of classic cycles (young, in seasonal competition), then switch to blast & cruise when ASIH becomes probable or HPG recovery is too difficult to maintain. This progression is documented as the typical trajectory of chronic competitors. The switch should ideally be medically supervised (endocrinology consultation, ASIH confirmation by repeated panel over 3-6 months, formal institution of permanent TRT with monitoring). Unsupervised B&C exposes to uncontrolled cardiovascular accumulation, while medicalized TRT-cruise maintains a cardio-neutral profile (Lincoff 2023, RCT TRAVERSE). For users considering the switch, several alternatives exist: (1) extend off-windows and attempt a complete restart, (2) medicalized formal TRT at physiological dose without blast, (3) long-term enclomiphene or clomid if HPG axis is partially recoverable. Sample B&C exit attempt timeline for younger user (< 35 years) after short B&C (< 2 years): W0 last blast ended, W1-W12 cruise dose taper from 150 mg/week to 100 mg/week to 75 mg/week (4 weeks each), W12-W16 stop completely with hCG 1500 IU EOD × 14 days, W16 SERM PCT (clomid + nolvadex × 8 weeks), W24 post-PCT panel, W36 12-month follow-up to assess HPG recovery, W48 confirmation. Realistic expectation: 50-70% partial recovery if young and B&C was short; older users or longer B&C usually require permanent TRT. Sample cycle preservation strategy: limit to 1-2 cycles per year, 12-week durations, clean PCTs, off-windows > 1.5× blast duration, monitor recovery panels carefully.

FAQ

Why do users switch to blast & cruise?: Several cumulative reasons (Coward 2013, Rasmussen 2016): (1) PCTs progressively less effective after each cycle, endogenous T no longer recovers to satisfactory levels; (2) gains drop during off with demotivation; (3) continuous competitive lifestyle (contest prep every 6-12 months) not allowing time for complete off phases; (4) desire to maintain a competitive physique permanently. B&C becomes a compromise for these users, but with increased cardiovascular and fertility risk.
Is B&C definitive?: Not necessarily, but difficult to reverse after several years. Smit 2021 (HAARLEM) documents that HPG recovery after moderate cycles is still possible at 12-18 months, but after prolonged B&C (3+ continuous years at repeated supraphysiological doses), ASIH becomes almost permanent in majority of users. Return to endogenous production > 400 ng/dL becomes improbable. The practice therefore becomes engaged long-term, even lifelong. Decision to be made with informed consent.
What monitoring under B&C?: Stricter than under classic cycles. Quarterly panel: CBC (target hematocrit < 52%), complete lipids (HDL, LDL, apoB), blood pressure, creatinine, ALT/AST (if oral compounds during blast), PSA (> 40 years), E2, T total and free. Annual echocardiography to monitor left ventricular hypertrophy (Baggish 2017). Preventive cardiology evaluation recommended in users > 35 years or with family history. Regular blood donation (target Hct < 50%) if chronic erythrocytosis.
Do classic cycles really preserve long-term health?: Better than B&C, but not as much as claimed. Pope 2014 (Endocrine Society) and Smit 2022 (HAARLEM review) document that even 'clean' repeated cycles generate cardiovascular accumulation (durably degraded HDL, intermittent hypertension, recurrent hematocrit) that can ultimately lead to effects equivalent to unsupervised B&C. The difference: classic cycles leave the possibility of stopping completely (HPG recovery preserved short-term), while B&C commits de facto. For optimal long-term health, minimize cumulated cycles.
How many cycles before probable ASIH?: Variable per individual and protocol. Coward 2013 documents that about 20-30% of chronic users (>5 cumulated cycles) develop persistent hypogonadism requiring permanent TRT. Aggravating factors: long cycles (>16 weeks), strong-suppression compounds (nandrolone, trenbolone), neglected PCTs, age > 35 years, comorbidities. To minimize: limit to 2 cycles per year maximum, moderate durations (12-14 weeks), clean PCTs, off-windows > blast duration, regular biological monitoring.
B&C and fertility?: Incompatible without support. B&C continually suppresses the HPG axis so stops spermatogenesis in a few months. To preserve fertility (Anawalt 2019, Liu 2002, Depenbusch 2002): hCG 500-1000 IU 2× per week SC continuously, in parallel with testosterone. This maintains spermatogenesis in majority of users. Smit 2021 shows that even under optimized protocol, sperm quality remains inferior to baseline. For users wishing to procreate in the near future, B&C not recommended without formal fertility plan.
Getting out of B&C: is it possible?: Difficult but not impossible in young users after short B&C. Smit 2021 (HAARLEM) shows partial HPG recovery at 12-18 months post-stop in some former users, but often incomplete. Possible exit scheme: (1) progressive dose decrease blast → cruise → complete stop over 6-12 months, (2) intensive PCT (hCG 1500 IU EOD × 14 d then clomid 50/25/25/25 + nolvadex 40/20/20/20 × 8 weeks), (3) biological monitoring over 12-24 months, (4) endocrinology consultation for evaluation. For users having done B&C > 5 years at high doses, complete natural recovery becomes improbable and permanent TRT becomes the pragmatic landing function.

Blast & Cruise vs Classic Cycles: complete comparison (continuity vs intermittence)

Critère	blast-and-cruise	traditional-cycles
Continuity	Continuous (never stops)	Intermittent (blast + off)
HPG axis recovery	None	Between cycles (with PCT)
ASIH risk	Very high	Moderate (with clean PCT)
Cumulative cardio exposure	Continuous, cumulative	Limited to blasts
Fertility	Suppressed (without hCG)	Recoverable post-PCT
Medical follow-up	Essential	Recommended
Target users	Advanced bodybuilders	Seasonal competitors
HPG management	PCT useless (axis suppressed)	Mandatory PCT

Quand choisir blast-and-cruise

Quand choisir traditional-cycles

Combinaison ?

FAQ

Why do users switch to blast & cruise?: Several cumulative reasons (Coward 2013, Rasmussen 2016): (1) PCTs progressively less effective after each cycle, endogenous T no longer recovers to satisfactory levels; (2) gains drop during off with demotivation; (3) continuous competitive lifestyle (contest prep every 6-12 months) not allowing time for complete off phases; (4) desire to maintain a competitive physique permanently. B&C becomes a compromise for these users, but with increased cardiovascular and fertility risk.
Is B&C definitive?: Not necessarily, but difficult to reverse after several years. Smit 2021 (HAARLEM) documents that HPG recovery after moderate cycles is still possible at 12-18 months, but after prolonged B&C (3+ continuous years at repeated supraphysiological doses), ASIH becomes almost permanent in majority of users. Return to endogenous production > 400 ng/dL becomes improbable. The practice therefore becomes engaged long-term, even lifelong. Decision to be made with informed consent.
What monitoring under B&C?: Stricter than under classic cycles. Quarterly panel: CBC (target hematocrit < 52%), complete lipids (HDL, LDL, apoB), blood pressure, creatinine, ALT/AST (if oral compounds during blast), PSA (> 40 years), E2, T total and free. Annual echocardiography to monitor left ventricular hypertrophy (Baggish 2017). Preventive cardiology evaluation recommended in users > 35 years or with family history. Regular blood donation (target Hct < 50%) if chronic erythrocytosis.
Do classic cycles really preserve long-term health?: Better than B&C, but not as much as claimed. Pope 2014 (Endocrine Society) and Smit 2022 (HAARLEM review) document that even 'clean' repeated cycles generate cardiovascular accumulation (durably degraded HDL, intermittent hypertension, recurrent hematocrit) that can ultimately lead to effects equivalent to unsupervised B&C. The difference: classic cycles leave the possibility of stopping completely (HPG recovery preserved short-term), while B&C commits de facto. For optimal long-term health, minimize cumulated cycles.
How many cycles before probable ASIH?: Variable per individual and protocol. Coward 2013 documents that about 20-30% of chronic users (>5 cumulated cycles) develop persistent hypogonadism requiring permanent TRT. Aggravating factors: long cycles (>16 weeks), strong-suppression compounds (nandrolone, trenbolone), neglected PCTs, age > 35 years, comorbidities. To minimize: limit to 2 cycles per year maximum, moderate durations (12-14 weeks), clean PCTs, off-windows > blast duration, regular biological monitoring.
B&C and fertility?: Incompatible without support. B&C continually suppresses the HPG axis so stops spermatogenesis in a few months. To preserve fertility (Anawalt 2019, Liu 2002, Depenbusch 2002): hCG 500-1000 IU 2× per week SC continuously, in parallel with testosterone. This maintains spermatogenesis in majority of users. Smit 2021 shows that even under optimized protocol, sperm quality remains inferior to baseline. For users wishing to procreate in the near future, B&C not recommended without formal fertility plan.
Getting out of B&C: is it possible?: Difficult but not impossible in young users after short B&C. Smit 2021 (HAARLEM) shows partial HPG recovery at 12-18 months post-stop in some former users, but often incomplete. Possible exit scheme: (1) progressive dose decrease blast → cruise → complete stop over 6-12 months, (2) intensive PCT (hCG 1500 IU EOD × 14 d then clomid 50/25/25/25 + nolvadex 40/20/20/20 × 8 weeks), (3) biological monitoring over 12-24 months, (4) endocrinology consultation for evaluation. For users having done B&C > 5 years at high doses, complete natural recovery becomes improbable and permanent TRT becomes the pragmatic landing function.